Table 1 Clinical and biochemical characteristics of the euglycemic and diabetic patients in the study population.
Total n = 452 | Euglycemic patients n = 359 (79.4%) | Diabetic patients n = 93 (20.6%) | p value | |
|---|---|---|---|---|
Gender (male/female) | 354/98 (78.3/21.7%) | 289/70 (80.5/19.5%) | 65/28 (69.9/30.1%) | 0.027 |
Age (years) | 60.8 ± 9.7 | 60.0 ± 9.5 | 63.8 ± 9.8 | 0.001 |
BMI | 27.5 ± 3.8 | 27.3 ± 3.6 | 28.4 ± 4.4 | 0.014 |
Height (cm) | 170.4 ± 8.4 | 170.6 ± 8.1 | 169.4 ± 9.4 | NS |
Weight (kg) | 79.9 ± 13.2 | 79.6 ± 13.2 | 81.2 ± 13.2 | NS |
SBP (supine mmHg) | 123.2 ± 19.1 | 122.7 ± 18.7 | 125.7 ± 20.7 | NS |
DBP (supine mmHg) | 80.2 ± 10.9 | 80.5 ± 10.9 | 79.0 ± 11.2 | NS |
Congestive heart failure | 45 (10.0%) | 16 (4.5%) | 29 (31.2%) | < 0.001 |
Concomitant medications | ||||
Acetylsalicylic acid | 392 (86.7%) | 317 (88.3%) | 75 (80.6%) | NS |
Beta blocker | 440 (97.3%) | 348 (96.9%) | 92 (98.9%) | NS |
ACE inhibitor/sartan | 179 (37.6%) | 123 (34.3%) | 47 (50.5%) | 0.004 |
Diuretic | 87 (19.2%) | 50 (13.9%) | 37 (39.8%) | < 0.001 |
Calcium channel blocker | 26 (5.8%) | 21 (5.8%) | 5 (5.4%) | NS |
Statin | 176 (38.9%) | 140 (39.0%) | 36 (38.7%) | NS |
Warfarin | 36 (8.0%) | 28 (7.8%) | 8 (8.6%) | NS |
Digoxin | 19 (4.2%) | 10 (2.8%) | 9 (9.7%) | 0.003 |
Amiodarone | 6 (1.3%) | 6 (1.7%) | 0 (0%) | NS |
Fasting glucose (mmol/l) | 6.4 ± 2.1 | 5.9 ± 1.4 | 8.3 ± 2.9 | < 0.001 |
Total cholesterol (mmol/l) | 5.4 ± 3.4 | 5.4 ± 3.7 | 5.3 ± 1.2 | NS |
HDL cholesterol (mmol/l) | 1.1 ± 0.3 | 1.2 ± 0.3 | 1.1 ± 0.3 | NS |
LDL cholesterol (mmol/l) | 3.4 ± 0.9 | 3.4 ± 0.9 | 3.4 ± 1.1 | NS |
Triglycerides (mmol/l) | 1.6 ± 0.9 | 1.5 ± 0.9 | 2.0 ± 1.1 | < 0.001 |